Tumor necrosis factor-alpha in pediatric HIV-1 infection.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Tumor necrosis factor-alpha in pediatric HIV-1 infection.

AIDS. 1992 Nov;6(11):1265-8. Unique Identifier : AIDSLINE MED/93112296
Ellaurie M; Rubinstein A; Special Immunology Service, Children's National Medical Center,; Washington, District of Columbia.

Abstract: OBJECTIVE: To evaluate the diagnostic and prognostic value of serum tumor necrosis factor-alpha (TNF-alpha) levels in HIV-1-infected children. DESIGN: Serum levels of TNF-alpha were evaluated in 57 HIV-1-infected symptomatic children aged between 7 months and 8 years. METHODS: TNF-alpha levels were determined by enzyme immunoassay. The sensitivity of the assay was 10 pg/ml. RESULTS: TNF-alpha levels (mean +/- s.d.) were significantly elevated in HIV-1-infected patients (285 +/- 390 pg/ml), compared with HIV-1-uninfected age-matched controls (22.7 +/- 4.9 pg/ml). Among HIV-1-infected children the highest levels of TNF-alpha were noted in those with Mycobacterium avium intracellulare (MAI) infection and those with interstitial lymphoid pneumonitis (LIP). In contrast, patients with Pneumocystis carinii pneumonia, progressive encephalopathy or cachexia did not have markedly elevated TNF-alpha levels. CONCLUSIONS: Serum TNF-alpha is increased in symptomatic HIV-1-infected children, with higher levels in children with LIP or MAI. Serum TNF-alpha levels are not diagnostic for cachexia or progressive encephalopathy.

Keywords: AIDS Dementia Complex/BLOOD/COMPLICATIONS AIDS-Related Opportunistic Infections/BLOOD Cachexia/BLOOD/COMPLICATIONS Child Child, Preschool Human HIV Infections/*BLOOD/COMPLICATIONS/DIAGNOSIS *HIV-1 Infant Mycobacterium avium-intracellulare Infection/BLOOD/COMPLICATIONS Pneumonia, Pneumocystis carinii/BLOOD/COMPLICATIONS Prognosis Pulmonary Fibrosis/BLOOD/COMPLICATIONS Support, U.S. Gov't, P.H.S. Tumor Necrosis Factor/*METABOLISM JOURNAL ARTICLE
930430
M9340804

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .